Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
Ferring began the double-blind, placebo-controlled, international Phase III Echo 1 and Echo 2 trials to evaluate 5 and 10 mg elobixibat daily in about 840 patients each. Patients will receive elobixib...